Health & Fitness
Mon, May 14, 2012Sun, May 13, 2012Sat, May 12, 2012Fri, May 11, 2012Thu, May 10, 2012Wed, May 9, 2012Tue, May 8, 2012Mon, May 7, 2012Sat, May 5, 2012Fri, May 4, 2012Thu, May 3, 2012Wed, May 2, 2012Tue, May 1, 2012Mon, April 30, 2012Sun, April 29, 2012Sat, April 28, 2012HeartWare Presentation at the Bank of America Merrill Lynch 2012 Health Care Conference to be Webcast
Published in Health and Fitness on Monday, May 7th 2012 at 13:51 GMT by Market Wire
HeartWare Presentation at the Bank of America Merrill Lynch 2012... -- FRAMINGHAM, Mass. and SYDNEY, May 7, 2012 /PRNewswire/ --
HeartWare Presentation at the Bank of America Merrill Lynch 2012 Health Care Conference to be Webcast
FRAMINGHAM, Mass. and SYDNEY, May 7, 2012 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: [ HTWR ] - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the Bank of America Merrill Lynch 2012 Health Care Conference at 3:00 p.m. PDT (6:00 p.m. EDT) on Wednesday, May 16, 2012. The conference is being held May 15-17, 2012 at the Encore at the Wynn, Las Vegas.
A live webcast of the Company's presentation at the conference will be available via a link provided at [ www.heartware.com ]. A replay of the webcast will be available for 90 days at the site after the presentation.
About HeartWare International
HeartWare International develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat Class IIIB / IV patients suffering from advanced heart failure. The HeartWare® Ventricular Assist System features the HVAD® pump, a small full-output circulatory support device (up to 10L/min flow) designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices. HeartWare has received CE Marking for the HeartWare System in the European Union and TGA approval in Australia. The device is currently the subject of United States clinical trials for two indications: bridge-to-transplant and destination therapy. For additional information, please visit [ www.heartware.com ].
HeartWare International, Inc. is a member of the Russell 2000® and its securities are publicly traded on The NASDAQ Stock Market and the Australian Securities Exchange.
HEARTWARE, HVAD, MVAD and HeartWare logos are registered trademarks of HeartWare, Inc.
For further information:
Christopher Taylor
HeartWare International, Inc.
Email: [ ctaylor@heartwareinc.com ]
Phone: +1 508 739 0864
SOURCE HeartWare International, Inc.
[ Back to top ] RELATED LINKS
[ http://www.heartware.com ]
